SEATTLE, Nov. 22, 2022 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in fireside chats and one-on-one meetings at the following upcoming investor conferences:
- 5th Annual Evercore ISI HealthCONx Conference – Fireside chat on Tuesday, November 29th at 10:30 am EST
- Piper Sandler 34th Annual Healthcare Conference – Fireside chat on Thursday, December 1st at 12:00 pm EST
To access the audio webcasts and subsequent archived recording of these and other company presentations, please visit the Investors section of Chinook’s website. The archived audio webcasts will remain available for replay on Chinook’s website for 90 days.
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody, is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 clinical trial in healthy volunteers. In addition, Chinook is advancing research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.
CONTACT: Contact: Noopur Liffick Vice President, Investor Relations & Corporate Communications [email protected] [email protected]
- ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BLUE - April 24, 2024
- LANTRONIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Lantronix, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - April 24, 2024
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Checkpoint, Sonder, and Perion and Encourages Investors to Contact the Firm - April 24, 2024